Details for Patent: 9,789,210

Which drugs does patent 9,789,210 protect, and when does it expire?

Patent 9,789,210 protects DEFINITY and DEFINITY RT and is included in one NDA.

This patent has twenty patent family members in thirteen countries.

Summary for Patent: 9,789,210

Title:	Methods for making ultrasound contrast agents
Abstract:	Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Inventor(s):	Robinson; Simon P. (Stow, MA), Siegler; Robert W. (Chelmsford, MA), Nguyen; Nhung Tuyet (Westford, MA), Onthank; David C. (Groton, MA), Anklekar; Tarakeshwar Vishwanath (Billerica, MA), Van Kirk; Charles Chester (Beverly, MA)
Assignee:	Lantheus Medical Imaging, Inc. (North Billerica, MA)
Application Number:	15/461,469
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,789,210

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lantheus Medcl	DEFINITY	perflutren	INJECTABLE;INTRAVENOUS	021064-001	Jul 31, 2001		RX	Yes	Yes						METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
Lantheus Medcl	DEFINITY RT	perflutren	INJECTABLE;INTRAVENOUS	021064-002	Nov 17, 2020		RX	Yes	Yes						METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

International Family Members for US Patent 9,789,210

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017291815
Brazil	112018074469
Canada	3025580